The diagnostic value of whole-genome sequencing and its role in risk stratification of children treated under the AML-MRD-2018 protocol
Pediatric Hematology/Oncology and Immunopathology · 30.06.2026 · 25 (2) · 12-24
DOI: 10.24287/j.1119 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Pediatric Hematology/Oncology and Immunopathology, online erschienen am 30.06.2026. Verfasst von Karina R. Iliasova und 14 weiteren Autor:innen. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Introduction
Risk stratification in pediatric acute myeloid leukemia (AML) is traditionally based on the detection of chromosomal rearrangements using conventional molecular cytogenetic methods. However, these approaches are limited in detecting structurally complex and new genomic alterations. Whole-genome sequencing (WGS) overcomes these limitations, ensuring detection of all types of structural variants and providing their comprehensive molecular characterization. Aim: to evaluate the capabilities of WGS in identifying chromosomal rearrangements in children with AML treated under the AML-MRD-2018 protocol. Materials and methods. Out of 723 patients enrolled in the AML-MRD-2018 protocol, 335 (46%) children aged 0–18 years (median age – 9 years) were included in the study. WGS was performed on the DNBSEQ-T7 platform (150 × 2), with a median sequencing depth of 112×. Structural variants were identified using the MANTA algorithm with subsequent verification using a genome visualizer and confirmation by polymerase chain reaction and Sanger sequencing.
Results
The results of WGS and standard testing methods were completely concordant in 228 (68%) out of 335 patients. WGS identified key stratifying translocations: KMT2Ar (n = 137; 41%), RUNX1::RUNX1T1 (n = 34; 10%), CBFB::MYH11 (n = 27; 8%), NUP98r (n = 19; 6%). In patients in whom standard methods had failed to detect markers, WGS revealed 26 rearrangements, including cryptic variants of KMT2A (n = 7), NUP98 (n = 5) and ERG rearrangements (n = 2), as well as rare fusion genes. Three novel fusion genes were identified. Overall, WGS provided additional clinically significant information in 40 cases, with an added diagnostic yield of 12%.
Conclusion
WGS effectively detects both recurrent and rare, cryptic, and structurally complex chromosomal rearrangements, while providing their thorough molecular characterization. The method allows for improved risk stratification and can serve as a basis for minimal residual disease monitoring, increasing diagnostic accuracy and the potential for treatment personalization.
Zitieren
APA
Iliasova, K. R., Abasov, R. K., Matveev, E. V., Itov, A. B., Kazakova, A. N., Kozeev, V. A., Popov, A. M., Plyasunova, S. A., Gurzhikhanova, M. K., Venyov, D. A., Kalinina, I. I., Novichkova, G. A., Maschan, A. A., Maschan, M. A., & Zerkalenkova, E. A. (2026). The diagnostic value of whole-genome sequencing and its role in risk stratification of children treated under the AML-MRD-2018 protocol. Pediatric Hematology/Oncology and Immunopathology, 25(2), 12-24. https://doi.org/10.24287/j.1119
Vancouver
Iliasova KR, Abasov RK, Matveev EV, Itov AB, Kazakova AN, Kozeev VA, et al. The diagnostic value of whole-genome sequencing and its role in risk stratification of children treated under the AML-MRD-2018 protocol. Pediatric Hematology/Oncology and Immunopathology. 2026;25(2):12-24. doi:10.24287/j.1119
BibTeX
@article{Iliasova2026,
author = {Iliasova, Karina R. and Abasov, R. Kh. and Matveev, E. V. and Itov, A. B. and Kazakova, A. N. and Kozeev, V. A. and Popov, A. M. and Plyasunova, S. A. and Gurzhikhanova, M. Kh. and Venyov, D. A. and Kalinina, I. I. and Novichkova, G. A. and Maschan, A. A. and Maschan, M. A. and Zerkalenkova, E. A.},
title = {The diagnostic value of whole-genome sequencing and its role in risk stratification of children treated under the AML-MRD-2018 protocol},
journal = {Pediatric Hematology/Oncology and Immunopathology},
year = {2026},
volume = {25},
number = {2},
pages = {12--24},
doi = {10.24287/j.1119}
}
EUVIMED